XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue by Source
The following table represents disaggregation of royalties, Captisol, service revenue and contract revenue (in thousands):

Three months endedSix months ended
June 30,June 30,
2020201920202019
Royalties
Kyprolis$5,481  $4,882  $9,886  $8,715  
Evomela1,199  1,144  2,775  2,055  
Other501  600  1,085  1,201  
Promacta—  —  —  14,193  
$7,181  $6,626  $13,746  $26,164  
Captisol$24,468  $8,549  $45,577  $17,508  
Service Revenue$4,582  $4,559  $7,939  $8,442  
Contract Revenue
License Fees$660  $1,990  $1,635  $2,840  
Milestone3,472  2,497  3,806  12,751  
Other1,057  766  1,878  766  
$5,189  $5,253  $7,319  $16,357  
Total$41,420  $24,987  $74,581  $68,471  
Schedule of Short-Term Investments
Our investments, excluding investment in Viking, consist of the following at June 30, 2020 and December 31, 2019 (in thousands):
June 30, 2020December 31, 2019
Amortized costGross unrealized gainsGross unrealized lossesEstimated fair valueAmortized costGross unrealized gainsGross unrealized lossesEstimated fair value
Short-term investments
     Bank deposits$269,114  $221  $(56) $269,279  $411,690  $188  $(3) $411,875  
     Corporate bonds55,380  125  (94) 55,411  63,818  161  —  63,979  
     Commercial paper163,590  134  —  163,724  210,525  43  (16) 210,552  
     Corporate equity securities4,506  634  (2,484) 2,656  4,506  416  (1,850) 3,072  
     Mutual fund151,223  —  (97) 151,126  250,635  —  (249) 250,386  
     Warrants—  177  —  177  —  125  —  125  
$643,813  $1,291  $(2,731) $642,373  $941,174  $933  $(2,118) $939,989  
Schedule of Available-for-Sale Debt Securities
The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):

June 30, 2020
Amortized CostFair Value
Within one year$414,505  $414,905  
After one year through five years73,579  73,509  
After five years—  —  
Total$488,084  $488,414  

The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):
Less than 12 months12 months or greaterTotal
Gross
Unrealized
Losses
Estimated
Fair Value
Gross
Unrealized
Losses
Estimated
Fair Value
Gross
Unrealized
Losses
Estimated
Fair Value
June 30, 2020
Bank deposits$(56) $30,015  $—  $—  $(56) $30,015  
Corporate bonds(94) 16,022  —  —  (94) 16,022  
Total$(150) $46,037  $—  $—  $(150) $46,037  
December 31, 2019
Bank deposits$(3) $58,584  $—  $—  $(3) $58,584  
Commercial paper(16) 79,363  —  —  (16) 79,363  
Total$(19) $137,947  $—  $—  $(19) $137,947  
Schedule of Goodwill and Other Identifiable Intangible Assets
Goodwill and other identifiable intangible assets consist of the following (in thousands):
June 30,December 31,
20202019
     Goodwill$103,369  $95,229  
Definite lived intangible assets
     Complete technology244,513  242,813  
          Less: accumulated amortization(1)
(57,053) (50,203) 
     Trade name2,642  2,642  
          Less: accumulated amortization(1,246) (1,180) 
     Customer relationships40,700  29,600  
          Less: accumulated amortization(14,261) (13,224) 
Total goodwill and other identifiable intangible assets, net$318,664  $305,677  
(1) accumulated amortization for complete technology includes immaterial amount of foreign currency translation adjustments for the complete technology acquired from the Vernalis acquisition.
Schedule of Commercial License Rights
Commercial license and other economic rights consist of the following (in thousands):
June 30, 2020December 31, 2019
Gross
Adjustments(1)
NetGross
Adjustments(2)
Net
Aziyo and CorMatrix$17,696  $(9,698) $7,998  $17,696  $(5,500) $12,196  
Palvella10,000  (10,000) —  10,000  (7,492) 2,508  
Selexis and Dianomi10,602  (7,994) 2,608  10,602  (5,216) 5,386  
     Total$38,298  $(27,692) $10,606  $38,298  $(18,208) $20,090  

(1) Amounts represent accumulated amortization to principal or research and development expenses of $21.7 million and credit loss adjustments of   $6.0 million as of June 30, 2020.
(2) Amounts represent accumulated amortization to principal or research and development expenses as of December 31, 2019.
Schedule of Accrued Liabilities
Accrued liabilities consist of the following (in thousands):
June 30,December 31,
20202019
Compensation$3,457  $1,986  
Professional fees964  1,135  
Amounts owed to former licensees413  381  
Royalties owed to third parties1,038  —  
Return reserve2,899  3,027  
Current operating lease liabilities1,728  1,242  
Accrued interest471  690  
Other1,858  1,375  
     Total accrued liabilities
$12,828  $9,836  
Schedule of Accounting for Share-Based Compensation The following table summarizes share-based compensation expense recorded as components of research and development expenses and general and administrative expenses for the periods indicated (in thousands):
Three months endedSix months ended
June 30,June 30,
2020201920202019
SBC - Research and development expenses$3,019  $2,528  $5,416  $4,655  
SBC - General and administrative expenses4,340  4,043  7,596  7,263  
$7,359  $6,571  $13,012  $11,918  
Schedule of Fair-Value Options Awarded to Employees and Directors
The fair-value for options that were awarded to employees and directors was estimated at the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions:

Three months endedSix months ended
June 30,June 30,
2020201920202019
Risk-free interest rate0.4%1.9%1.1%2.4%
Dividend yield
Expected volatility69%40%55%43%
Expected term5.15.94.85.2
Schedule of Computation of Basic and Diluted Earnings per Share
The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in thousands):
Three months endedSix months ended
June 30,June 30,
2020201920202019
Weighted average shares outstanding:16,055  19,558  16,292  20,000  
Dilutive potential common shares:
     Restricted stock40  —  —  38  
     Stock options599  —  —  761  
Shares used to compute diluted income per share16,694  19,558  16,292  20,799  
Potentially dilutive shares excluded from calculation due to anti-dilutive effect7,832  7,457  8,988  7,243